Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for p70 S6K drug discovery. View selected modalities below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT Kinase) | RPS6KB1 (p70 S6K) Recombinant Protein. High purity (>95%), Endotoxin <1EU/μg, Sequence Verified. | View RPS6KB1 Products |
| Mutant Panel | Drug Resistance Mutants (T389A, F396A, etc.) for resistance mechanism and selectivity screening. Sequence Verified. | View RPS6KB1 Products |
| Gene Delivery | RPS6KB1 Promise-ORF Lentivirus for stable cell line construction (HEK293T optimized). | View RPS6KB1 Products |
| Benchmark Ab | Anti-p70 S6K Benchmark Antibody. Recombinant positive control for pathway validation. | View RPS6KB1 Products |
| Validator | p70 S6K siRNA Set for knockdown verification and specificity controls (PROTAC baseline). | View RPS6KB1 Products |
| Isoform Control | RPS6KB2 (S6K2) Recombinant Protein for paralog selectivity counter-screening. High purity (>95%). | View RPS6KB2 Products |
| Substrate | RPS6 (Ribosomal Protein S6) for kinase activity assays. Sequence Verified. | View RPS6 Products |
| Related Target: mTOR | Upstream kinase; essential for dual-inhibition combination therapies. | View MTOR Products |
| Related Target: AKT1 | Compensatory feedback loop target requiring simultaneous monitoring. | View AKT1 Products |
Critical Assay Challenges & Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (S6K1 vs S6K2) | Homolog panel proteins (RPS6KB1 and RPS6KB2) strictly sequence verified (>95% purity). |
| Kinome Cross-reactivity | High purity (>95%) recombinant AGC kinases for rigorous selectivity profiling. |
| Lack of Controls | Clinical Benchmark Antibodies included for western blot and ELISA standardization. |
| False Positives in Degradation | Validated siRNA included for specificity checks against PROTAC off-targets. |
| Drug Resistance Mutation Screening | Custom mutant panel (ATP-binding site, activation loop). Theoretical MW and purity confirmed. |
| Active Kinase Assay | High-purity recombinant enzyme expressed in HEK293 (properly folded for activity assays). |
| Off-target Counter-Screening | AGC family homologs (RPS6KA1/RSK1, AKT1) available for selectivity panels. |
| Cellular Validation | Validated siRNA and Lentivirus ORF for genetic rescue experiments. |
Live p70 S6K R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for p70 S6K (RPS6KB1) therapeutics is evolving, with major players shifting focus from traditional ATP-competitive small molecules to allosteric inhibitors and targeted protein degraders (PROTACs). As first-generation therapies revealed challenges with upstream PI3K/AKT feedback loop hyperactivation, the next wave of R&D is heavily targeting combination therapies and scaffolding-ablating modalities to bypass compensatory resistance mechanisms. Combination therapies with PI3K/AKT inhibitors are advancing to Phase II, and the demand for robust selectivity and resistance profiling has become critical for differentiation. Selective S6K1 isoform inhibitors and PROTAC degraders are now at the forefront to overcome resistance mechanisms, particularly in breast cancer and solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (ATP-competitive) | Novartis, Sanofi, eFFECTOR Therapeutics, Array BioPharma | Breast Cancer, Solid Tumors, HR+ Breast Cancer, CRPC | Isoform Selectivity Assay (Need High-Purity S6K1/S6K2 Proteins) |
| PROTAC / Degrader | Emerging Biotechs, Arvinas, Cullgen | Refractory Tumors, Refractory Solid Tumors | Degradation Validation (Need Sequence Verified Endogenous Antibodies and Lentivirus ORF for rescue) |
| Allosteric Inhibitor | AstraZeneca, Biogen | Metabolic Disorders, Cancer | Conformational Binding Assay (Need mutant panel) |
| Combination Therapy | Roche, AstraZeneca, Novartis, Lilly | PI3K/AKT/mTOR mutated Cancers, Triple-negative Breast Cancer | Pathway Analysis (Need comprehensive PI3K pathway recombinant panels and MTOR co-expression) |